Literature DB >> 15794732

Acne vulgaris: a review of antibiotic therapy.

Audrey W Tan1, Hiok-Hee Tan.   

Abstract

Antibiotic therapy has been integral to the management of inflammatory acne vulgaris for many years. Systemic antibiotics work via antibacterial, anti-inflammatory and immunomodulatory modes of action, and have been found to be useful in managing moderate-to-severe acne. Commonly prescribed antibiotics include tetracyclines, erythromycin and trimethoprim, with or without sulfamethoxazole. In selecting the appropriate antibiotic for patients needing to receive topical or systemic antibiotic therapy, the clinician should take into account the severity of the acne, cost-effectiveness, the safety profile of the drug and the potential for development of resistance. The widespread and long-term use of antibiotics over the years has unfortunately led to the emergence of resistant bacteria. The global increase in the antibiotic resistance of Propionibacterium acnes may be a significant contributing factor in treatment failures. It is therefore essential that clinicians prescribing antibiotics for the treatment of acne adopt strategies to minimise further development of bacterial resistance. This includes addressing compliance issues, using combination therapies, avoiding prolonged antibiotic treatment, and avoiding concomitant topical and oral antibiotics with chemically dissimilar antibiotics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15794732     DOI: 10.1517/14656566.6.3.409

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  8 in total

Review 1.  [Systemic acne therapy].

Authors:  A Thielitz; H Gollnick
Journal:  Hautarzt       Date:  2005-11       Impact factor: 0.751

2.  Oral antibiotics in acne vulgaris: therapeutic response over 5 years.

Authors:  J Adawiyah; G Priya; B Roshidah
Journal:  Malays Fam Physician       Date:  2010-12-31

Review 3.  Oral Doxycycline in the Management of Acne Vulgaris: Current Perspectives on Clinical Use and Recent Findings with a New Double-scored Small Tablet Formulation.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2015-05

Review 4.  Blue light for infectious diseases: Propionibacterium acnes, Helicobacter pylori, and beyond?

Authors:  Tianhong Dai; Asheesh Gupta; Clinton K Murray; Mark S Vrahas; George P Tegos; Michael R Hamblin
Journal:  Drug Resist Updat       Date:  2012-07-28       Impact factor: 18.500

5.  Comparing efficacy of Montelukast versus doxycycline in treatment of moderate acne.

Authors:  Elham Behrangi; Elahe Arasteh; Tahmine Tavakoli; Golnaz Mehran; Najmolsadat Atefi; Shooka Esmaeeli; Zahra Azizian
Journal:  J Res Med Sci       Date:  2015-04       Impact factor: 1.852

6.  Efficacy of mupirocin and rifampin used with standard treatment in the management of acne vulgaris.

Authors:  Farzin Khorvash; Fatemeh Abdi; Hessam H Kashani; Farahnaz Fatemi Naeini; Fariborz Khorvash
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

7.  BMAL1 regulates Propionibacterium acnes-induced skin inflammation via REV-ERBα in mice.

Authors:  Feng Li; Luomin Lin; Yiting He; Guanghui Sun; Dong Dong; Baojian Wu
Journal:  Int J Biol Sci       Date:  2022-03-21       Impact factor: 6.580

8.  Staphylococcus aureus in Acne Pathogenesis: A Case-Control Study.

Authors:  Farzin Khorvash; Fatemeh Abdi; Hessam H Kashani; Farahnaz Fatemi Naeini; Tahmineh Narimani
Journal:  N Am J Med Sci       Date:  2012-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.